NewAmsterdam Pharma Co N.V. 8-K

What Happened
NewAmsterdam Pharma Co N.V. filed a Form 8‑K on May 7, 2026 (Item 2.02) to announce corporate updates and its financial results for the quarter ended March 31, 2026. The company furnished a press release dated May 7, 2026 as Exhibit 99.1 with the reported quarterly results. The filing was signed by Chief Financial Officer Ian Somaiya.

Key Details

• Filing date: May 7, 2026; reporting period: quarter ended March 31, 2026 (Q1 2026).
• Item reported: 2.02 — Results of Operations and Financial Condition; press release provided as Exhibit 99.1.
• Signature: Ian Somaiya, Chief Financial Officer, signed the 8‑K.
• Cover page interactive XBRL file included (Exhibit 104).

Why It Matters
This 8‑K notifies investors that NewAmsterdam has released its quarterly earnings and related corporate updates; the press release (Exhibit 99.1) will contain the specific figures for revenue, earnings (or loss), cash position and any guidance. Retail investors should read the attached press release for the exact earnings and revenue figures and consider how those results compare to expectations, as the announced quarterly results can influence the company’s stock and near‑term outlook. No other material events (e.g., executive changes, mergers or bankruptcy) were disclosed in this filing.